

The potential for Iterum Therapeutics (ITRM) stock to reach $5.00 today, given FDA approval for oral sulopenem in treating uncomplicated urinary tract infections (uUTI), is a subject of speculation. Here's an analysis based on current information:
- Current Price and Recent Trends:
- The closing price of ITRM on October 24, 2024, was $1.171.
- The stock has shown a 1-week percentage change of 13.59% and a 1-month percentage change of 5.41%2.
- Technical Indicators:
- The stock's 5-day moving average is $1.13, the 10-day moving average is $1.07, and the 20-day moving average is $1.043. These indicators suggest a short-term upward trend.
- Market Sentiment:
- The market sentiment towards ITRM is bullish, as indicated by the Bullish rating from InvestorsObserver Stock Sentiment Indicator45.
- Upcoming FDA Decision:
- The FDA is expected to make a decision on the approval of oral sulopenem for the treatment of uUTI by October 25, 202467.
- The anticipation of this decision has likely influenced the stock's recent positive performance.
- Price Target:
- HC Wainwright has maintained a Buy rating with a $5.00 price target on ITRM89. This price target is based on the expectation of FDA approval and the potential for sulopenem to become the first oral penem approved in the U.S.
- Potential Impact of FDA Approval:
- If the FDA approves oral sulopenem for uUTI, it could be a significant milestone for Iterum Therapeutics, potentially leading to increased investor confidence and a positive stock price reaction.
- The approval would also validate the company's efforts and the potential for sulopenem to address an unmet medical need.
Conclusion: While it's possible that ITRM's stock price could reach $5.00 today if the FDA approves oral sulopenem for uUTI, this is largely speculative and depends on several factors, including the strength of the market's reaction to the news, the broader market conditions, and any specific details or restrictions associated with the FDA approval. The current technical indicators and market sentiment suggest that the stock has the potential for upward movement, but whether it can reach $5.00 is uncertain and would require a significant positive catalyst, such as FDA approval.
